33.70MMarket Cap-928P/E (TTM)
3.1800High2.8292Low8.71KVolume3.1800Open3.1818Pre Close26.03KTurnover0.14%Turnover RatioLossP/E (Static)11.74MShares5.500052wk High-9.47P/B17.69MFloat Cap1.077552wk Low--Dividend TTM6.16MShs Float5000.0000Historical High--Div YieldTTM11.03%Amplitude1.0775Historical Low2.9900Avg Price1Lot Size
Akari Therapeutics Stock Forum
Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity
•Prioritization of Peak’s ADC cancer therapeutic platform technology and Akari’s PAS-nomacopan for Geographic Atrophy, a disabling ophthalmic disease•Akari Therapeutics announces leadership changes in separate Akari press release
BOSTON and PLEASANTON, May 1, 2024 (GLOBE NEWSWIRE) - Akari Therapeutics, Plc ...
8 MINUTES AGO, 8:00 AM EDT
VIA GLOBENEWSWIRE
No comment yet